Related Experiment Video
Updated: Jan 17, 2026
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.9K
Survival Outcomes in Cutaneous Angiosarcoma: A Meta Analysis.
Aneri Bhargav Patel1,2, William Driscoll3, Ajay Nair Sharma1
1Department of Dermatology, University of California, Irvine, California.
Summary
Tumor location and patient age significantly impact angiosarcoma survival. Treatment type did not affect outcomes, suggesting personalized care is crucial for this rare cancer.
Area of Science:
- Oncology
- Dermatology
- Surgical Pathology
Background:
- Cutaneous angiosarcoma is a rare, aggressive cancer with poor prognosis.
- Limited evidence exists to guide treatment due to disease heterogeneity and few large trials.
Purpose of the Study:
- To evaluate survival outcomes based on treatment modalities and clinical stages in cutaneous angiosarcoma patients.
- To conduct a meta-analysis of existing studies to better understand prognostic factors.
Main Methods:
- Systematic literature search for studies reporting cutaneous angiosarcoma treatment and outcomes.
- Extracted patient-level data from 159 patients across 9 studies.
- Performed survival analysis using Kaplan-Meier estimates and Cox regression, stratifying by stage.
Main Results:
- Early-stage angiosarcoma patients demonstrated longer survival and delayed recurrence/metastasis versus mid/late-stage, though not statistically significant.
- Tumor location was the strongest survival predictor in advanced stages; younger age predicted better survival in early stages.
- Treatment modality and surgical approach did not independently correlate with survival outcomes.
Conclusions:
- Tumor location and patient age are key prognostic indicators for angiosarcoma.
- Treatment modality did not significantly influence survival or recurrence rates.
- Individualized treatment strategies and further research into survival determinants are warranted.
More Related Videos
Related Concept Videos
01:21Cancer Survival Analysis
650
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
650
01:20Comparing the Survival Analysis of Two or More Groups
561
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
561
01:24Kaplan-Meier Approach
577
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
577